From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes a recent transition to being an approved/specified/listed/qualified/etc. choice inside buyers' systems, such that future business can arrive without discrete selling events, and that this is new and not yet reflected in results. Key points from transcript: - They discuss VAC (Value Analysis Committee) approvals for full-thickness skin defects. They have 178 submissions, 8 rejections, and expect 46 accounts to be approved in Q2. This suggests they are getting approved by hospital committees, which is a form of being added to a formulary or approved list. However, is this new? They launched full-thickness in June 2023, and they have been adding accounts. But they say "we only added a total of 73 new accounts" since launch. So they are getting approvals, but it's an ongoing process. The question is whether they convey that this access is new and that most volume is still ahead. - They also mention RECELL GO is nearing FDA approval (180-day review ends May 30). That is pending, not yet approved. So that's not a current status. - They mention PermeaDerm launch, but that's a product launch, not a gateway. - They talk about expanding into wound care, but that's strategic. - They mention international distribution agreements, but those are ordinary reseller agreements. - They mention vitiligo initiative, but that's future. The key is VAC approvals. Are these approvals a "gateway" that inserts the company into the system? Yes, VAC approval means the hospital has approved the product for use, so it becomes a listed product. But is it new? They have been getting approvals since launch. However, they say they expect 46 approvals in Q2, which is a significant number. But they also say they had 73 total accounts added since launch. So the process is ongoing. Do they convey that this is recent and that most volume is still ahead? They say "we believe we will continue to become more efficient in closing new accounts." They also say "we expect 46 accounts to be approved in the second quarter." That suggests a ramp-up. But is it a "meaningful portion of future business can now arrive without a discrete selling event"? Once a hospital approves, the product is on the formulary, so subsequent orders may be easier. But they still need to train and sell to individual physicians.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.